-
公开(公告)号：GB2369360A
公开(公告)日：2002-05-29
申请号：GB0130563
申请日：2000-06-19
Applicant: CELLTECH R&D LTD
Inventor： BATCHELOR MARK JAMES , MOFFAT DAVID , DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R 1 is a hydrogen atom or a straight or branched chain alkyl group: R 2 is a-X 1 -R 3 group where X 1 is a direct bond or a linker atom or group, and R 3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis.
-
公开(公告)号：AU5548800A
公开(公告)日：2001-01-09
申请号：AU5548800
申请日：2000-06-19
Applicant: CELLTECH R&D LTD
Inventor： BATCHELOR MARK JAMES , MOFFAT DAVID FESTUS CHARLES , DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
公开(公告)号：NZ532713A
公开(公告)日：2005-10-28
申请号：NZ53271302
申请日：2002-10-16
Applicant: CELLTECH R&D LTD
IPC: A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04 , C07D495/04
Abstract: Disclosed are compounds of formula (Ia), wherein: A is -C(Rb)= or -C(Rb)(Rc)-, Ra, Rb and Rc are independently H or optionally substituted alkyl, X is O or S, Y is N, CH or substituted C, n is 0 or 1, Alk1 is an optionally substituted aliphatic or heteroaliphatic chain, L1 is a bond, or linker atom or group, Cy1 is H, or optionally substituted cycloaliphatic, polycycloaliphati, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic, Ar is an optionally substituted aromatic or heteroaromatic. The compounds are used in the manufacture of medicaments for the treatment of immune and inflammatory diseases.
-
公开(公告)号：CA2540881A1
公开(公告)日：2005-05-12
申请号：CA2540881
申请日：2004-10-22
Applicant: CELLTECH R&D LTD
Inventor： HUTCHINGS MARTIN CLIVE , LAING VICTORIA ELIZABETH , TREVITT GRAHAM PETER , ALEXANDER RIKKI PETER , DAVIS JEREMY MARTIN
IPC: C07D495/04 , A61K31/4365 , A61P29/00 , A61P37/00 , C07D221/00 , C07D333/00
Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 3-position by an arylcarbonyl or heteroaryl-carbonyl moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
-
公开(公告)号：NO20050306L
公开(公告)日：2005-03-16
申请号：NO20050306
申请日：2005-01-19
Applicant: CELLTECH R&D LTD
IPC: A61K31/4743 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/02 , A61P7/04 , A61P7/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P31/16 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D495/04 , A61K31/44
Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F(1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH═ group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
-
Patent Agency Ranking
公开(公告)号：CA2528602A1
公开(公告)日：2004-12-29
申请号：CA2528602
申请日：2004-06-18
Applicant: CELLTECH R&D LTD
IPC: C07D495/04 , A61K31/4365 , A61P29/00
Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2 - position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety , being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorde rs.
-
公开(公告)号：HU0401718A2
公开(公告)日：2004-12-28
申请号：HU0401718
申请日：2002-10-16
Applicant: CELLTECH R&D LTD
IPC: A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04 , C07D495/04
Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a -N- atom or a -N(R b )-, -C(R b )- or -C(R b )(R C )- group; R a , R b and R c is each independently a hydrogen atom or an optionally substituted C 1-6 alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk 1 is an optionally substituted aliphatic or heteroaliphatic chain L 1 is a covalent bond or a linker atom or group; Cy 1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis
-
公开(公告)号：NO20041975D0
公开(公告)日：2004-05-13
申请号：NO20041975
申请日：2004-05-13
Applicant: CELLTECH R&D LTD
IPC: A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04 , C07D495/04 , C07D
Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a -N- atom or a -N(R b )-, -C(R b )- or -C(R b )(R C )- group; R a , R b and R c is each independently a hydrogen atom or an optionally substituted C 1-6 alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk 1 is an optionally substituted aliphatic or heteroaliphatic chain L 1 is a covalent bond or a linker atom or group; Cy 1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis
-
公开(公告)号：ZA200109841B
公开(公告)日：2003-02-26
申请号：ZA200109841
申请日：2001-11-29
Applicant: CELLTECH R&D LTD
Inventor： BATCHELOR MARK JAMES , MOFFAT DAVID FESTUS CHARLES , DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04 , C07D , A61K , A61P
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
公开(公告)号：HU0201535A2
公开(公告)日：2002-08-28
申请号：HU0201535
申请日：2000-06-19
Applicant: CELLTECH R&D LTD
Inventor： BATCHELOR MARK JAMES , DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE , MOFFAT DAVID FESTUS CHARLES
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.024 seconds)
